Jilin Xidian Pharmaceutical Technology Development Co., Ltd
Initial public offering and listing on GEM
Suggestive announcement of listing announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate, complete and timely without false records, misleading statements or major omissions.
With the consent of Shenzhen Stock Exchange, the RMB common shares issued by the company will be listed on the gem of Shenzhen Stock Exchange on February 23, 2022. The full text of the listing announcement and the full text of the prospectus of the initial public offering of shares will be disclosed on the following five information disclosure websites: http://www.cn.info.com.cn China Securities Network (www.cs. Com. CN.) China Securities Network (www.cn. Stock. Com.) Securities Times (www.stcn. Com.) Securities Daily (www.zqrb. CN.), For investors to consult.
QR code of web page: cninfo.com I. listing overview
(I) stock abbreviation: West Point pharmaceutical
(II) Stock Code: 301130
(III) total share capital after IPO: 803943 shares
(IV) number of initial public offering shares: 20200986 shares, including 1041444 shares with circulation restrictions, the sales restriction period is 6 months, and the number of shares without circulation restrictions is 19159542 shares, which will be listed and traded from the date of listing.
2、 Risk tips
The company’s shares will be listed on the growth enterprise market of Shenzhen Stock Exchange, which has high investment risk. GEM companies have the characteristics of unstable performance, high operation risk and high delisting risk, and investors are facing greater market risk. Investors should fully understand the investment risks of the gem and the risk factors disclosed by the company, and make investment decisions prudently.
According to the industry classification guidelines for listed companies (revised in 2012) issued by China Securities Regulatory Commission, the industry of West Point pharmaceutical is “pharmaceutical manufacturing industry (C27)”. As of February 8, 2022 (T-4), the average static P / E ratio of the industry released by China Securities Index Co., Ltd. in the latest month was 37.80 times. The issuance price of 22.55 yuan / share corresponds to the lower diluted P / E ratio of the issuer before and after deducting non recurring profits and losses in 2020, which is 42.95 times higher than the average static P / E ratio of the industry in the latest month released by China Securities Index Co., Ltd. on February 8 (T-4) 2022, with an excess range of 13.62%; It is 45.55 times lower than the average static P / E ratio of comparable companies after deducting non-profit in 2020.
As of February 8, 2022 (T-4), the valuation levels of comparable listed companies are as follows:
In 2020, deduct the static securities code corresponding to the stock deducted on T-4 in 2020. The securities are referred to as non front EPS and non back EPS. The closing price (yuan / state p / E ratio – deducted P / E ratio – deducted (yuan / share) (yuan / share) is not front (2020A) and not back (2020A)
002923.SZ Zhuhai Rundu Pharmaceutical Co.Ltd(002923) 0.7316 0.6125 20.80 28.43 33.96
300254.SZ Shanxi C&Y Pharmaceutical Group Co.Ltd(300254) -1.1509 -1.2603 7.76 -6.74 -6.16
300436.SZ Fujian Cosunter Pharmaceutical Co.Ltd(300436) 0.0934 0.0093 34.48 369.3 3721.99
300584.SZ Nanjing Hicin Pharmaceutical Co.Ltd(300584) 0.4603 0.4420 38.89 84.5 87.98
600513.SH Jiangsu Lianhuan Pharmaceutical Co.Ltd(600513) 0.3577 0.3399 8.67 24.24 25.51
688566.SH Jiangsu Jibeier Pharmaceutical Co.Ltd(688566) 0.6939 0.6103 21.20 30.55 34.73
Mean value (excluding outliers – Shanxi C&Y Pharmaceutical Group Co.Ltd(300254) , Fujian Cosunter Pharmaceutical Co.Ltd(300436) ) 41.93 45.55
Data source: wind information, data as of February 8, 2022.
Note 1: if there is mantissa difference in the calculation of P / E ratio, it is caused by rounding;
Note 2: EPS before / after deduction of non recurring profit and loss in 2020 = net profit attributable to the parent before / after deduction of non recurring profit and loss in 2020 / total share capital on T-4 day.
The issuance price of 22.55 yuan / share corresponds to the lower diluted P / E ratio of the issuer before and after deducting non recurring profits and losses in 2020, which is 42.95 times higher than the average static P / E ratio of the industry in the latest month released by China Securities Index Co., Ltd. on February 8 (T-4) 2022, with an excess range of 13.62%; It is 45.55 times lower than the average static P / E ratio of comparable companies after deducting non-profit in 2020. There is a risk that the decline of the issuer’s share price will bring losses to investors in the future.
The underwriter should be aware of the potential risk of the listing, and the underwriter should be aware of the potential risk of the listing. The underwriter should be cautious in making investment decisions, and the underwriter should be aware of the potential risk of the listing. The underwriter should be cautious in making investment decisions, so as to avoid the risk of the listing.
The company reminds investors to pay attention to the investment risks at the initial stage of IPO listing. Investors should fully understand the risks and rationally participate in the trading of new shares. 3、 Contact information
1. Issuer: Jilin Xidian Pharmaceutical Technology Development Co., Ltd
Address: No. 777, West Point Street, Panshi Economic Development Zone, Jilin Province
Contact: Meng Yonghong
Tel: 0432-65888277
Fax: 0432-65888299
2. Sponsor (lead underwriter): Haitong Securities Company Limited(600837)
Address: No. 689, Guangdong Road, Huangpu District, Shanghai
Contact: Zhao qionglin, Huang Lei
Tel: 021-23219000
Fax: 021-63410707
(there is no text on this page, which is the seal page of the suggestive announcement of the listing announcement of Jilin West Point Pharmaceutical Technology Development Co., Ltd. on its initial public offering and listing on the GEM)
Jilin Xidian pharmaceutical science and Technology Development Co., Ltd. (this page has no text, which is the seal page of the suggestive announcement of the listing announcement of Jilin Xidian pharmaceutical science and Technology Development Co., Ltd. on its initial public offering of shares and listing on the GEM)
Haitong Securities Company Limited(600837) mm / DD / yy
